Photo by engin akyurt on UnsplashIf you’re on a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound, and you’ve recently noticed more hair on your pillow, in the shower drain, or on your brush, you’re not alone. Hair loss has become one of the most commonly discussed side effects among users of these weight-loss drugs. And for many, it feels confusing, frustrating, and sometimes even frightening.
Let’s talk about what the research is starting to show, what might be causing the shedding, and most importantly, what you can do about it.
What the Science Says About GLP-1s and Hair Loss
So far, the drug manufacturers haven’t highlighted hair loss as a major concern, but recent independent studies are raising important questions. One 2025 real-world cohort study found that patients taking GLP-1/GIP drugs like tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy) were about twice as likely to develop alopecia areata compared to those on other weight loss medications like bupropion-naltrexone. The hazard ratio was 2.09 (Burke et al., 2025). That’s a significant increase.
Interestingly, the researchers didn’t find evidence that these medications directly damage hair follicles. Instead, the hair loss seems linked to rapid weight loss itself, along with nutritional changes that occur when people eat much less than their bodies are used to.
This echoes findings from an earlier 2023 review, which documented temporary hair loss (called telogen effluvium) following bariatric surgery and other forms of quick weight loss (McCoy et al., 2023). The faster the weight loss, the greater the risk of nutrient depletion, hormonal shifts, and inflammatory stress. All of these can disrupt the hair growth cycle.
It’s Not Just the Drug. It’s the Metabolic Shift.
Your hair is not essential for survival, so during a calorie deficit, the body often diverts nutrients toward more vital systems like the brain, heart, and muscles. That leaves your follicles undernourished, which can push more of them into the “resting” phase of the hair cycle. After a few weeks or months, those hairs fall out all at once.
Many people report that the shedding begins 8 to 12 weeks after starting the medication or reaching a milestone in weight loss. That timing lines up with how telogen effluvium usually works.
It’s important to remember this kind of hair loss is typically reversible. But it still requires your attention and care.
What You Can Do Right Now
Here’s what I recommend for anyone on GLP-1 medications who’s worried about hair loss:
- Slow it down if possible. Weight loss doesn’t need to be a sprint. Gradual change helps your body adapt and reduces stress on your hair.
- Focus on plant-based proteins. Foods like lentils, beans, tofu, edamame, and quinoa offer protein without inflammation. Plus, they come packaged with fiber, zinc, biotin, and iron, which are all important for hair strength.
- Don’t skimp on fats. Healthy fats like avocado, walnuts, chia seeds, and olive oil support hormone health and scalp hydration.
- Make sure you’re getting enough B vitamins and iron. These are often depleted in rapid weight loss and are key to keeping your hair in the growth phase.
- Consider a quality multivitamin. Look for one designed for hair and skin support, but always check with your provider before adding new supplements. Make sure that the ingredients are verified.
- Treat your scalp kindly. Ditch the harsh shampoos. Use gentle products and don’t overwash. Scalp massage with rosemary oil may also help boost circulation.
A Reminder of What’s Most Important
I want to end with this: if your hair is thinning right now, it does not mean you’ve done something wrong. You are not vain or weak for being upset about it. Hair is part of how we express ourselves. It’s okay to care about this.
The most empowering thing you can do is understand what’s happening, support your body with real nourishment, and ask for help if you need it.
You are not alone, and you’re not broken. Your body is always trying to protect you. Let’s help it do just that.
References
Burke, J. P., Kalagara, S., Alvarez‑Cespedes, D., Sechi, A., & Tosti, A. (2025). Glucagon‑like peptide‑1 receptor agonist medications and hair loss: A retrospective cohort study. Journal of the American Academy of Dermatology, 92(5), 1141–1143. https://doi.org/10.1016/j.jaad.2025.01.046
Godfrey, H., Leibovit‑Reiben, Z., Jedlowski, P., & Thiede, R. (2025). Alopecia associated with semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology, 39(2), e153–e154. https://doi.org/10.1111/jdv.20197
Kang, D. H., Kwon, S. H., Sim, W. Y., & Lew, B. L. (2024). Telogen effluvium associated with weight loss: A single center retrospective study. Annals of Dermatology, 36(6), 384–388. https://doi.org/10.5021/ad.24.043
Recent Comments